November 05, 2018

Indivumed opens US-Headquarter in Frederick, MD

Friday, November 2nd 2018. With a symposium about „Personalized Medicine Depends on Tissue Quality“ and an opening ceremony in presence of Benjamin Wu, Maryland Deputy Secretary of Commerce, Jan Gardner, Frederick County Executive and members of the County Council as well as 120 international guests the new Indivumed Headquarter was officially opened.

Read More

October 24, 2018

Indivumed to Exhibit at the 30th EORTC-NCI-AACR SYMPOSIUM ,Dublin, November 13–16

Hosted by the European Organisation for Research and Treatment of Cancer (EORTC), the National Cancer Institute (NCI) and the American Association for Cancer Research (AACR), the 2018 Symposium brings together academics, scientists and pharmaceutical industry representatives from across the globe to discuss the latest innovations in drug development, target selection and the impact of new discoveries in molecular biology.

Read More

July 25, 2018

Indivumed Launches New Biospecimen Product Lines

Indivumed is known for providing high-quality, ischemia-controlled biospecimens from within our clinical network. In addition to these Premium Grade specimens, we now offer two new lines of formalin-fixed paraffin-embedded (FFPE) tissue biospecimens – Advanced Grade and Basic Grade.

Read More

July 25, 2018

Indivumed Officially Launches Premium Grade Longitudinal Cell-Free Plasma Biospecimens

Indivumed is known for providing high-quality, ischemia-controlled biospecimens from within our clinical network. To further support the fight against cancer, we now offer high-quality Premium Grade longitudinal cell-free plasma specimens from within our growing oncologist network.

Read More


December 18, 2018

Indivumed Announces an International Partnership with IMCB to Establish an Asian-Centric Multiomics Cancer Database for Personalized Oncology

December 18th, 2018 Singapore / Hamburg, Germany - Indivumed GmbH today announced the launch of the “Cancer Library Initiative”, an operation to further accelerate precision diagnostics and personalised treatment for cancer patients, in collaboration with A*STAR’s Institute of Molecular and Cell Biology (IMCB).

Read More

July 03, 2018

Indivumed signs agreement with IMCB to build the first global, multiomics cancer database

Indivumed GmbH and A*STAR’s Institute of Molecular and Cell Biology (IMCB) in Singapore have signed an agreement to perform proteomic and phosphoproteomic analysis of thousands of tissue samples from Indivumed’s unique biobank.

Read More

January 16, 2018

The Salk Institute and Indivumed Partner to Advance Global Cancer Research

Salk and Indivumed have established a strategic partnership to advance research in precision oncology and personalized medicine by utilizing the highest quality molecular and clinical data in cancer

Read More

January 09, 2018

Investment Plan for Europe: EIB grants loan of EUR 40m to Indivumed

The European Investment Bank (EIB) will provide a loan of EUR 40m to Indivumed GmbH, a physician-led, integrated global oncology company providing high-content tumour data and an optimum quality biobank to third parties such as biopharmaceutical companies and research institutes.

Read More

Product Information



Personalized Oncology – Why Tissue Is the Issue When Characterizing Tumor Expression

Opening Remarks and The Importance of Biobanking on Personalized Medicine
Speaker: Carolyn Compton

The Challlenge and Importance of Standardizing Pre-Analytical Variables in Surgical Pathology Specimens for Clinical Care and Translational Research
Speaker: David Hicks

How to Assess Tissue Quality to Improve Tissue Diagnostics
Speaker: Jim Crawford

The Future of Personalized Medicine in Oncology Has Begun
Speaker: John Marshall

IndivuType: Indivumed's Global Cancer Database Solution for Drug Development and Patient Care
Speaker: Hartmut Juhl

The Indivumed Biobank